Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
Hesham ElghazalyHamdy A AzimHope S RugoDavid CameronSandra M SwainCurigliano GiuseppeNadia HarbeckDebu TripathyBanu K ArunMatti AaproMartine PiccartFatima CardosoJoseph GligorovHagar I ElghazawyNagi S El SaghirFrederique Penault-LlorcaEdith A PerezPhilip PoortmansHany AbdelazizHeba M El-ZawahryLoay KassemMohamed SabryGiuseppe VialeSana Al-SukhunNeven GadoJessica W T LeungLobna Ezz ElarabMaria João CardosoKhaled Abdel KarimMeteb FoheidiMerit M ElmaadawyPierFranco ConteAshraf S M SelimAlaa KandilRasha M KamalRuslan M PaltuevValentina GuarneriOmalkhair AbulkhairOmar ZakariaMehra GolshanRoberto OrecchiaManal ElMahdyAhmed M Abdel-AzizNermean Bahie EldinPublished in: Cancer (2024)
The consensus recommendations addressed different escalation and de-escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.